US Impact Equity Fund

Kapitalverlustrisiko. Die Wertentwicklung in der Vergangenheit ist kein zuverlässiger Hinweis auf die aktuellen oder künftigen Ergebnisse. Bitte berücksichtigen Sie bei der Wahl eines Produkts oder einer Strategie auch andere Faktoren.

Die aufgeführten Fonds sind keine vollständige Liste der verfügbaren Fonds. Besuchen Sie www.funds.troweprice.com, um die gesamte Palette der von T. Rowe Price angebotenen Fonds zu sehen, einschließlich derer, die ökologische und soziale Merkmale als Teil ihres Anlageprozesses berücksichtigen. Aktuelle Informationen über die Anlagestrategie der einzelnen T. Rowe Price-Fonds finden Sie in den jeweiligen KID und Prospekten der Fonds.

Risiken

Nähere Informationen: siehe „Risikohinweise“

Aktienrisiko
ESG-Risiko
Geografisches Konzentrationsrisiko
Investmentfondsrisiko
Emittentenkonzentrationsrisiko
Verwaltungsrisiko
Marktrisiko
Operationelles Risiko
Sektorkonzentrationsrisiko
Small-/Mid-Cap-Risiko

Typisches Anlegerprofil

Anleger, die mittel- bis langfristig investieren möchten.

Der Teilfonds kann für Anleger ansprechend sein, die:

an positiven ökologischen und sozialen Auswirkungen interessiert
sind,
neben einer finanziellen Rendite auch eine positive ökologische
oder soziale Wirkung erzielen möchten,
die Risiken des Fonds, einschließlich der mit der Anlage in USAktien verbundenen Risiken, verstehen und akzeptieren

30-Juni-2022 - Shawn T. Driscoll, Portfoliomanager,

HCA Healthcare is the largest publicly traded hospital operator in the U.S. We sold out of our holding, as we saw the lucrative benefits that HCA had derived from the coronavirus pandemic begin to wane, and we wanted to book profits and reinvest in a higher conviction name, albeit another COVID beneficiary, Quest Diagnostics.
Quest Diagnostics is one of the largest independent clinical laboratories and diagnostic testing companies in the U.S. Given its scale, Quest was and is a central player in COVID testing. We appreciate management's focus on sustaining growth rates while transitioning the business to a post-COVID environment. We believe Quest has opportunities to leverage their advanced diagnostic capabilities as well as to grow their direct consumer testing franchise.
Within biotechnology, we eliminated our position in AbbVie in favor of Regeneron Pharmaceuticals. Regeneron is a commercial-stage biotechnology company with an attractive biologic treatment portfolio and drug pipeline anchored by blockbusters: retinal disease treatment Eylea and Dupixent, a monoclonal antibody used to treat allergic diseases. Recently, the firm reached an agreement with Sanofi to acquire the full global rights to Libtayo, another promising immuno-oncology drug franchise that Regeneron hopes to extend.
We bought Progressive, a property and casualty insurance carrier and major player in the personal auto insurance market. We believe that Progressive's competitive advantages, including its low expense ratio, superior data and analytics, and excellent management systems, provide it with higher underwriting leverage and stronger margin potential that, in our view, should drive consistent return growth and a deserved premium valuation versus peers.
We view swapping out our position in Bank of New York Mellon for a new holding in JPMorgan Chase as a quality upgrade at an attractive risk/reward trade-off within financials. JPMorgan Chase is one of the four largest money center banks in the U.S. with an even mix of retail and wholesale businesses. We favor JPMorgan's scale, robust loan growth, attractive fee businesses, relatively conservative underwriting, and experienced management team in an uncertain macro backdrop.
On a recent pullback in June, we initiated a position in Ameren, an electric and gas utility company serving Missouri and Illinois. We think that Ameren is a high-quality utility with a long runway for growth, as it has a solid management team, constructive�regulatory jurisdictions, multiple areas for upside optionality including renewables, and a top-tier balance sheet, and, in our view, is well-positioned for an inflationary environment.
We substantially sold down our holding in XCEL Energy and used the funds to purchase Ameren, which we view as an upgrade in quality in the utility space.
We eliminated Charter Communications in favor of other ideas with more upside potential. We felt that Charter may struggle to grow its subscriber base as competition in the space increases.

30-Juni-2022 - Shawn T. Driscoll, Portfoliomanager,

Shares of discount retailer Dollar General advanced double digits this quarter, bucking the downward spiral of consumer discretionary stocks overall. The company, known for its rural neighborhood footprint, broad selection of merchandise, and value-based off-price strategy, released solid earnings in May that exceeded expectations for topline revenue and earnings. Same-store sales increased as consumers, squeezed by inflation and higher gas prices, depended more on shopping at their local Dollar General. We continue to like the company's below-average cyclicality, strong value proposition of low prices and convenience, and shareholder-friendly capital deployment.
Despite a pullback in April?after releasing disappointing first-quarter earnings facing tough year-ago comparables?shares of specialty retailer O'Reilly Automotive outperformed the overall consumer discretionary sector over the period. Given the firm's pricing power, competitively advantaged supply chain and distribution capabilities, and strong positioning in the nondiscretionary auto parts market, we think that O'Reilly should benefit as consumers are keeping their existing vehicles longer, and we believe that the firm has the potential to enhance its competitive position by gaining market share through its recently introduced pricing initiative.
Broadridge Financial Solutions is a technology solutions provider that manages mandated investor communications, such as proxy distribution and voting, for corporate issuers, institutional investors, and broker-dealers. Amid the volatile macro backdrop, Broadridge delivered steady growth and fiscal third-quarter earnings that beat expectations. Management stated that the firm is on track to deliver full-year earnings toward the higher end of its target range and�reiterated its ability to drive continued margin expansion along with topline growth. In our view, Broadridge is set up well to benefit from secular tailwinds in bank/brokerage outsourcing, which should support ongoing business momentum.
KLA is a capital equipment company that provides testing and control systems for the semiconductor industry. Shares of KLA held up better than pure semiconductor names through the current sell-off, as the firm was able to navigate through supply chain issues and a challenging backdrop to deliver margins and earnings ahead of consensus. We believe that KLA remains well positioned given that the ever-rising complexity in the space should continue to drive the need for KLA's systems to enhance productivity.